LDH Cancer Research Results

LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition

Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
98- QC,    Quercetin postconditioning attenuates myocardial ischemia/reperfusion injury in rats through the PI3K/Akt pathway
- in-vivo, Stroke, NA
*Bcl-2↑, *BAX↓, *Bax:Bcl2↓, *cardioP↑, *Akt↑, *PI3K↑, *LDH↓,
2332- RES,    Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism
- Review, Var, NA
Glycolysis↓, GLUT1↓, PFK1↓, Hif1a↓, ROS↑, PDH↑, AMPK↑, TumCG↓, TumCI↓, TumCP↓, p‑NF-kB↓, SIRT1↑, SIRT3↑, LDH↓, PI3K↓, mTOR↓, PKM2↓, R5P↝, G6PD↓, TKT↝, talin↓, HK2↓, GRP78/BiP↑, GlucoseCon↓, ER Stress↑, Warburg↓, PFK↓,
323- Sal,  AgNPs,    Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy
- in-vitro, BC, MDA-MB-231 - in-vitro, Ovarian, A2780S
TumCD↑, LDH↓, MDA↑, SOD↓, ROS↑, GSH↓, Catalase↓, MMP↓, P53↑, P21↑, BAX↑, Bcl-2↓, Casp3↑, Casp9↑, Apoptosis↑, TumAuto↑,
4488- Se,  Chit,  PEG,    Anticancer effect of selenium/chitosan/polyethylene glycol/allyl isothiocyanate nanocomposites against diethylnitrosamine-induced liver cancer in rats
- in-vivo, Liver, HepG2 - in-vivo, Nor, HL7702
tumCV↓, Apoptosis↑, *GSH↑, *VitC↑, *VitE↑, *SOD↑, *GPx↑, *GR↑, ALAT↓, ALP↓, AST↓, LDH↓, selectivity↑, eff↑,
4480- SeNPs,  Chit,    Biogenic synthesized selenium nanoparticles combined chitosan nanoparticles controlled lung cancer growth via ROS generation and mitochondrial damage pathway
- in-vitro, Lung, A549 - in-vitro, Nor, HK-2
selectivity↑, *toxicity↓, ROS↑, mtDam↑, Apoptosis↑, LDH↑,
4443- SeNPs,    Bioogenic selenium and its hepatoprotective activity
- in-vivo, LiverDam, NA
*hepatoP↑, *AST↓, *ALAT↓, *LDH↓, *lipid-P?,
3184- SFN,    The Integrative Role of Sulforaphane in Preventing Inflammation, Oxidative Stress and Fatigue: A Review of a Potential Protective Phytochemical
- Review, Nor, NA
*NRF2↑, *Inflam↓, *NF-kB↓, *ROS↓, *BioAv↝, *BioAv↝, *BioAv↝, *BioAv↝, *cardioP↑, *GPx↑, *SOD↑, *Catalase↑, *GPx↑, *HO-1↑, *NADPH↑, *NQO1↑, *LDH↓, *hepatoP↑, *ALAT↓, *AST↓, *IL6↓,
3330- SIL,    Mechanistic Insights into the Pharmacological Significance of Silymarin
- Review, Var, NA
*neuroP↑, *hepatoP↑, *cardioP↑, *antiOx↓, *NLRP3↓, *NAD↑, ROS↓, NLRP3↓, TumCMig↓, *COX2/PTGS2↓, *iNOS↓, *MPO↓, *AChE↓, *LDH↓, *Telomerase↓, *Fas↓,
1284- SK,    Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy
- in-vitro, Melanoma, RPMI-8226 - in-vitro, Melanoma, U266
Ferroptosis↑, LDH↓, ROS↑, Iron↑, lipid-P↑, ATP↓, HMGB1↓, GPx4↓, MDA↑, SOD↓, GSH↓,
2181- SK,    Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2
- in-vitro, BC, MCF7 - in-vitro, Lung, A549 - in-vitro, Cerv, HeLa
Glycolysis↓, lactateProd↓, GlucoseCon↓, PKM2↓, LDH∅,
3040- SK,    Pharmacological Properties of Shikonin – A Review of Literature since 2002
- Review, Var, NA - Review, IBD, NA - Review, Stroke, NA
*Half-Life↝, *BioAv↓, *BioAv↑, *BioAv↑, *Inflam↓, *TNF-α↓, *other↑, *MPO↓, *COX2/PTGS2↓, *NF-kB↑, *STAT3↑, *antiOx↑, *ROS↓, *neuroP↑, *SOD↑, *Catalase↑, *GPx↑, *Bcl-2↑, *BAX↓, cardioP↑, AntiCan↑, NF-kB↓, ROS↑, PKM2↓, TumCCA↑, Necroptosis↑, Apoptosis↑, DNAdam↑, MMP↓, Cyt‑c↑, LDH↝,
3953- Taur,    Role of taurine in regulation of intracellular calcium level and neuroprotective function in cultured neurons
- in-vitro, AD, NA
*neuroP↑, *Ca+2↓, *LDH↓,
3955- Taur,    Mechanism of neuroprotective function of taurine
- in-vitro, Nor, NA
*Ca+2↓, *MMP↑, *Apoptosis↓, *Bcl-2↑, *cal2↓, *LDH↓,
2093- TQ,    Regulation of NF-κB Expression by Thymoquinone; A Role in Regulating Pro-Inflammatory Cytokines and Programmed Cell Death in Hepatic Cancer Cells
- in-vitro, Liver, HepG2 - in-vitro, Nor, NA
TumCD↑, selectivity↑, Casp3↑, DLC1↑, NF-kB↑, LDH↑, *toxicity↓,
3398- TQ,  5-FU,    Impact of thymoquinone on the Nrf2/HO-1 and MAPK/NF-κB axis in mitigating 5-fluorouracil-induced acute kidney injury in vivo
- in-vivo, Nor, NA
*RenoP↑, *TAC↑, *ROS↓, *lipid-P↓, *p38↓, *MAPK↓, *NF-kB↓, *NRF2↑, *HO-1↑, *MDA↓, *GPx↑, *GSR↑, *Catalase↑, *BUN↓, *LDH↓, *IL1β↓,
3559- TQ,    Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *AChE↓, AntiCan↑, *cardioP↑, *RenoP↑, *neuroP↑, *hepatoP↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↑, TumCCA↑, angioG↓, *NF-kB↓, *TLR2↓, *TLR4↓, *MyD88↓, *TRIF↓, *IRF3↓, *IL1β↓, *IL6↓, *IL12↓, *NRF2↑, *COX2/PTGS2↓, *VEGF↓, *MMP9↓, *cMyc↓, *cycD1/CCND1↓, *TumCP↓, *TumCI↓, *MDA↓, *TGF-β↓, *CRP↓, *Casp3↓, *GSH↑, *IL10↑, *iNOS↑, *lipid-P↓, *SOD↑, *H2O2↓, *ROS↓, *LDH↓, *Catalase↑, *GPx↑, *AChE↓, *cognitive↑, *MAPK↑, *JNK↑, *BAX↓, *memory↑, *Aβ↓, *MMP↑,
3140- VitC,    Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest
- in-vitro, PC, MIA PaCa-2 - in-vitro, Nor, HEK293
citrate↓, FASN↓, ACLY↓, LDH↓, Glycolysis↓, Warburg↓, PDK1 / PDPK1↓, GLUT1↓, LDHA↓, ECAR↓, PDH↑, Synergy↑,
3144- VitC,    Some characteristics of Rabbit muscle phosphofructokinase-1 inhibition by ascorbate
- in-vitro, Nor, NA
PFK1↓, LDH↓,
3139- VitC,    Vitamin C and sodium bicarbonate enhance the antioxidant ability of H9C2 cells and induce HSPs to relieve heat stress
- in-vitro, Nor, H9c2
*Apoptosis∅, *LDH∅, *MDA∅, *SOD↓, eff↝,
7915- VT,    A Brief Review on the Neuroprotective Mechanisms of Vitexin
- Review, AD, NA - Review, Park, NA
*neuroP↑, *Inflam↓, *cognitive↓, *motorD↑, *BACE/β-secretase↓, *LDH↓, *AChE↓, *BChE↓, *ROS↓,
7914- VT,    Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells
- vitro+vivo, Lung, A549
tumCV↓, selectivity↑, Cyt‑c↑, MMP↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, TumCG↓, mtDam↑, LDH↑, Bax:Bcl2↑, cl‑Casp3↑,
7913- VT,    Review of the effects of vitexin in oxidative stress-related diseases
- Review, Nor, NA
*antiOx↑, *ROS↓, *lipid-P↓, *memory↑, *Stroke↓, *cardioP↑, *neuroP↑, *Inflam↓, *NRF2↑, *HO-1↑, *NQO1↑, *GRP78/BiP↑, *CHOP/DDIT3↓, *BACE/β-secretase↓, *ChE↓, *AChE↓, *BChE↓, *GSH↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL33↓, *LDH↓, *MDA↓, *SOD↑,
2621- Wog,    Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review
- Review, Var, NA
Hif1a↓, MCT4↓, LDH↓, lactateProd↓, ECAR↓, TumCP↓, Glycolysis↓,

Showing Research Papers: 101 to 123 of 123
Prev Page 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 123

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   Catalase↓, 2,   GPx↑, 1,   GPx4↓, 1,   GSH↓, 13,   GSH↑, 3,   GSTs↑, 1,   H2O2↑, 2,   HO-1↓, 2,   HO-1↑, 2,   Iron↑, 1,   lipid-P↓, 1,   lipid-P↑, 5,   MDA?, 1,   MDA↓, 3,   MDA↑, 5,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 3,   PYCR1↓, 1,   RNS↑, 1,   ROS↓, 6,   ROS↑, 53,   mt-ROS↑, 1,   SOD↓, 4,   SOD↑, 3,   Thiols↓, 1,   TKT↝, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CS↓, 1,   EGF↓, 1,   mitResp↓, 2,   mtDam↑, 11,   OCR↓, 3,   OXPHOS↓, 3,   mt-OXPHOS↓, 2,   PDH↓, 4,   PDH↑, 4,   PDH↝, 1,   SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 3,   ALAT↓, 3,   AMPK↑, 5,   p‑AMPK↑, 1,   ATP↓, 10,   CAIX/CA9↓, 1,   citrate↓, 2,   ECAR↓, 4,   FASN↓, 3,   G6PD↓, 3,   GAPDH↓, 4,   GLO-I↓, 1,   GLS↓, 1,   GlucoseCon↓, 6,   GlucoseCon↑, 1,   glut↓, 1,   GlutaM↓, 2,   Glycolysis↓, 23,   Glycolysis↑, 1,   p‑GSK‐3β↓, 1,   HAGH/GLO2↓, 1,   HK2↓, 11,   HK2↑, 1,   lactateProd↓, 6,   lactateProd↑, 1,   LDHA↓, 3,   LDL↓, 1,   MCT4↓, 1,   NAD↑, 1,   NADH:NAD↓, 1,   NADPH↓, 2,   PDK1 / PDPK1↓, 4,   PFK↓, 4,   PFK1↓, 4,   PFK1↑, 1,   PFK2↓, 1,   PKM2↓, 8,   PPP↓, 1,   Pyruv↑, 1,   R5P↝, 1,   SIRT1↓, 1,   SIRT1↑, 1,   TCA↓, 3,   TCA↑, 1,   Warburg↓, 4,   Warburg↑, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 1,   Apoptosis?, 2,   Apoptosis↓, 2,   Apoptosis↑, 33,   mt-Apoptosis↑, 1,   ASC↓, 1,   Bak↑, 3,   BAX↓, 3,   BAX↑, 21,   Bax:Bcl2↓, 1,   Bax:Bcl2↑, 6,   Bcl-2↓, 26,   Bcl-xL↓, 2,   BID↑, 1,   BNIP3?, 1,   Casp↓, 1,   Casp↑, 3,   Casp1↓, 1,   cl‑Casp1↓, 1,   proCasp1↓, 1,   Casp12↑, 2,   Casp3↓, 4,   Casp3↑, 30,   cl‑Casp3↑, 7,   Casp7↑, 2,   cl‑Casp7↑, 1,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 11,   cl‑Casp9↑, 4,   Cyt‑c↑, 23,   DR5↑, 2,   Endon↑, 1,   FADD↑, 1,   Fas↓, 1,   Fas↑, 2,   FasL↑, 1,   Ferroptosis↑, 1,   GSDMD↑, 1,   iNOS↓, 2,   iNOS↑, 1,   Mcl-1↓, 3,   Necroptosis↑, 1,   P2X7↓, 1,   p38↓, 1,   p38↑, 3,   Pyro↑, 1,   survivin↓, 1,   TRAIL⇅, 1,   TRAILR↑, 1,   TumCD↑, 6,   XIAP↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 14,   Akt↑, 1,   p‑Akt↓, 2,   CIP2A↓, 1,   CREB↓, 1,   EGFR↓, 2,   ERK↓, 6,   ERK↑, 2,   FGFR1↓, 2,   HER2/EBBR2↓, 2,   JAK2↓, 1,   JNK↓, 1,   JNK↑, 3,   p‑JNK↑, 2,   MAPK↓, 5,   MAPK↑, 1,   mTOR↓, 10,   p‑mTOR↓, 1,   P70S6K↓, 1,   PI3K↓, 12,   p‑PI3K↓, 1,   PKA↓, 1,   PKCδ↓, 2,   PTEN↑, 1,   Raf↓, 1,   RAS↓, 1,   STAT↓, 1,   STAT3↓, 4,   STAT6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,   ATF4↑, 1,   cMyc↓, 6,   cMyc↑, 1,   DNMTs↓, 1,   FOXO3↑, 1,   H3↓, 1,   HDAC↓, 1,   HDAC1↓, 1,   HDAC8↓, 1,   miR-145↑, 1,   miR-21↑, 1,   miR-34a↑, 1,   OCT4↓, 2,   other↑, 1,   SOX2↓, 1,   TET3↑, 1,   tumCV?, 1,   tumCV↓, 11,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   CHOP/DDIT3↑, 5,   p‑eIF2α↓, 1,   p‑eIF2α↑, 2,   ER Stress↑, 8,   GRP78/BiP↓, 1,   GRP78/BiP↑, 5,   HSP70/HSPA5↓, 2,   HSP90↓, 1,   IRE1↑, 1,   PERK↑, 1,   UPR↑, 1,   XBP-1↓, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

autoF↓, 1,   Beclin-1/ATG6↑, 1,   CTSB↓, 1,   CTSD↓, 1,   CTSL↑, 1,   LC3B-II↑, 1,   LC3II↑, 5,   lysosome↓, 1,   p62↓, 1,   p62↑, 1,   TumAuto↑, 10,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 10,   mt-DNAdam↑, 1,   hTERT/TERT↓, 2,   P53↑, 12,   P53↝, 1,   p‑P53↑, 1,   PARP↓, 2,   PARP↑, 2,   cl‑PARP↑, 9,   cl‑PARP1↑, 1,   PCNA↓, 8,   Telomerase↓, 1,   TOP1↓, 1,   TP53↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 2,   CDK2↑, 2,   CDK4↓, 3,   CDK6↓, 2,   CHK1↓, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 12,   Ki-67↓, 6,   MAD↓, 1,   P21↓, 2,   P21↑, 6,   p‑pRB↓, 1,   TumCCA↓, 1,   TumCCA↑, 24,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CSCs↓, 8,   FGF↓, 1,   IGF-1↓, 1,   IGFBP3↑, 1,   Ki-67↓, 6,   Nanog↓, 1,   NOTCH↓, 5,   NOTCH1↓, 1,   NOTCH1↑, 1,   NOTCH3↓, 1,   Shh↓, 1,   TumCG↓, 13,   TumCG∅, 1,   TumCP↓, 21,   Wnt↓, 2,  

Migration(tgid=13) ⓘ

AXL↓, 1,   Ca+2?, 1,   Ca+2↑, 7,   DLC1↑, 1,   E-cadherin↑, 8,   EMT↓, 9,   EMT↝, 1,   EpCAM↓, 1,   F-actin↓, 1,   FAK↓, 1,   p‑FAK↓, 1,   Fibronectin↓, 1,   MMP-10↓, 1,   MMP1↓, 2,   MMP2↓, 10,   MMP7↓, 1,   MMP9↓, 11,   MMPs↓, 3,   N-cadherin↓, 4,   PDGF↓, 1,   Slug↓, 3,   Smad1↑, 1,   Snail↓, 3,   talin↓, 1,   TET1↑, 1,   TGF-β↓, 1,   TGF-β↑, 1,   TIMP1↓, 1,   TIMP2↑, 2,   TIMP3↑, 1,   TSP-1↑, 1,   TumCI↓, 10,   TumCMig↓, 10,   TumCMig↑, 1,   TumMeta↓, 8,   Twist↓, 2,   uPA↓, 1,   uPAR↓, 1,   Vim↓, 2,   ZEB2↓, 1,   α-SMA↓, 1,   α-SMA↑, 1,   β-catenin/ZEB1↓, 5,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 11,   CD31/PECAM-1↓, 1,   eNOS↑, 1,   HIF-1↓, 1,   Hif1a↓, 12,   Hif1a↑, 1,   Hypoxia↑, 1,   VEGF↓, 10,   VEGFR2/KDR/Flk1↓, 4,  

Barriers & Transport(tgid=15) ⓘ

CLDN1↓, 1,   GLUT1↓, 7,   GLUT1↑, 1,   GLUT2↓, 1,   GLUT3↓, 1,   MMP↓, 19,   MMP↑, 2,   MMP↝, 1,   MPT↑, 1,   TRPM7↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 1,   COX2/PTGS2↓, 6,   COX2/PTGS2↑, 2,   CXCR4↓, 1,   DR4↑, 1,   HMGB1↓, 1,   ICAM-1↓, 1,   IL1↓, 2,   IL10↓, 4,   IL1β↓, 7,   IL1β↑, 2,   IL4↓, 1,   IL6↓, 9,   IL8↓, 2,   Inflam↓, 6,   MCP1/CCL2↓, 1,   MCT1↓, 1,   NF-kB↓, 21,   NF-kB↑, 1,   p‑NF-kB↓, 1,   NLRP3↓, 4,   p65↓, 1,   PD-1↓, 1,   PGE2↓, 2,   RAGE↑, 1,   TLR4↓, 3,   TNF-α↓, 7,   TNF-α↑, 3,  

Protein Aggregation(tgid=19) ⓘ

AGEs↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   ER-α36↓, 1,   PPARα↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 5,   ChemoSen↓, 1,   ChemoSen↑, 12,   CompStab↑, 2,   Dose?, 1,   Dose↝, 3,   Dose∅, 3,   eff↓, 6,   eff↑, 16,   eff↝, 3,   P-gp/ABCB1↓, 1,   RadioS↑, 6,   selectivity↑, 14,   Synergy↑, 13,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 2,   ALAT↓, 3,   ALP↓, 3,   AR↓, 1,   AST↓, 1,   CRP↓, 1,   EGFR↓, 2,   HER2/EBBR2↓, 2,   hTERT/TERT↓, 2,   IL6↓, 9,   LDH?, 1,   LDH↓, 52,   LDH↑, 19,   LDH↝, 3,   LDH∅, 1,   p‑LDH↓, 1,   e-LDH↑, 2,   i-LDH↓, 1,   RAGE↑, 1,   TP53↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 10,   AntiTum↑, 5,   cardioP↑, 2,   chemoP↑, 4,   ChemoSideEff↓, 2,   hepatoP↑, 1,   neuroP↑, 2,   OS↑, 4,   radioP↑, 1,   RenoP↑, 2,   toxicity↝, 1,   TumVol↓, 3,   TumW↓, 2,   Weight↑, 2,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,   Sepsis↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 401

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 14,   Catalase↑, 16,   GPx↑, 13,   GPx4↑, 1,   GSH↑, 14,   GSR↓, 1,   GSR↑, 4,   GSTs↑, 2,   H2O2↓, 2,   HO-1↑, 9,   i-Iron↓, 1,   Keap1↓, 1,   lipid-P?, 1,   lipid-P↓, 12,   MDA↓, 14,   MDA∅, 1,   MPO↓, 3,   NOX4↓, 1,   NQO1↑, 3,   NRF2↓, 2,   NRF2↑, 13,   ROS↓, 30,   SOD↓, 1,   SOD↑, 18,   SOD1↑, 1,   SOD2↑, 2,   TAC↑, 3,   TBARS↓, 1,   Trx1↑, 1,   VitC↑, 1,   VitE↑, 1,   xCT/SLC7A11↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mitResp↑, 1,   mtDam↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   ACSL4↓, 1,   ALAT↓, 12,   AMPK↑, 2,   ATP↑, 1,   ATP∅, 1,   glucose↓, 1,   GSK‐3β↓, 1,   H2S↑, 1,   lactateProd↓, 1,   NAD↑, 1,   NADPH↑, 1,  

Cell Death(tgid=5) ⓘ

AIF↓, 1,   Apoptosis↓, 4,   Apoptosis∅, 1,   BAX↓, 3,   Bax:Bcl2↓, 1,   Bcl-2↑, 4,   Casp↓, 1,   Casp3↓, 3,   Casp9↓, 1,   Cyt‑c↓, 1,   Fas↓, 1,   Ferroptosis↓, 1,   iNOS↓, 5,   iNOS↑, 1,   necrosis↓, 1,   p38↓, 1,   Pyro↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   Akt↑, 1,   CK2↓, 1,   JNK↓, 1,   JNK↑, 1,   MAPK↓, 3,   MAPK↑, 1,   PI3K↓, 1,   PI3K↑, 1,   STAT↓, 1,   STAT3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cMyc↓, 1,   HDAC↓, 1,   other↓, 1,   other↑, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   GRP78/BiP↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PCNA↓, 1,   Telomerase↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   Ki-67↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Ki-67↓, 1,   TumCP↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   Ca+2↓, 3,   Ca+2↝, 1,   cal2↓, 1,   LRP1↑, 1,   MMP9↓, 1,   MUC1↑, 1,   TGF-β↓, 2,   TGF-β1↑, 1,   TumCI↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 1,   NO↓, 5,   VCAM-1↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 2,   IBI↑, 1,   MMP↓, 2,   MMP↑, 2,   TRPC1↓, 1,   TRPM7↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 10,   ICAM-1↓, 1,   IL10↑, 4,   IL12↓, 1,   IL18↓, 1,   IL1β↓, 11,   IL2↓, 1,   IL33↓, 1,   IL4↓, 1,   IL6↓, 13,   IL8↓, 2,   Imm↑, 2,   INF-γ↓, 1,   Inflam↓, 19,   Inflam↑, 1,   IRF3↓, 1,   MyD88↓, 1,   NeuroI↓, 1,   NF-kB↓, 13,   NF-kB↑, 1,   NLRP3↓, 2,   PGE2↓, 4,   RAGE↓, 1,   TLR2↓, 3,   TLR4↓, 3,   TNF-α↓, 12,   TRIF↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

Astr↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   Ach↑, 1,   AChE↓, 7,   BChE↓, 2,   ChE↓, 1,   MAOA↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 5,   Aβ42↓, 1,   BACE/β-secretase↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

GR↑, 1,   PPARα↝, 1,   PPARγ↓, 1,   PPARγ↑, 2,   p‑PPARγ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 3,   BioAv↝, 6,   BioAv∅, 1,   ChemoSen↑, 1,   Dose↑, 1,   Dose↝, 4,   Dose∅, 1,   eff↑, 2,   eff↝, 1,   Half-Life↝, 4,   Half-Life∅, 1,   Synergy↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 12,   ALP↓, 3,   AST↓, 13,   BMD↑, 1,   BP↓, 3,   BUN↓, 1,   creat↓, 1,   CRP↓, 2,   IL6↓, 13,   LDH↓, 42,   LDH↑, 3,   LDH∅, 1,   RAGE↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   antiAll↑, 1,   AntiArt↑, 2,   AntiCan↑, 1,   AntiDiabetic↑, 6,   antiPs↑, 1,   cardioP↑, 22,   chemoP↑, 1,   chemoPv↑, 1,   cognitive↓, 1,   cognitive↑, 10,   hepatoP↑, 15,   Learn↑, 1,   memory↑, 8,   motorD↑, 2,   neuroP↑, 25,   Obesity↓, 2,   Pain↓, 1,   radioP↑, 1,   RenoP↑, 5,   Strength↑, 1,   Stroke↓, 3,   toxicity↓, 7,   toxicity∅, 2,   Wound Healing↑, 2,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 3,   GutMicro↑, 1,  
Total Targets: 204

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
13 Silver-NanoParticles
7 Galloflavin
5 Carvacrol
4 Propolis -bee glue
4 Quercetin
3 3-bromopyruvate
3 Ashwagandha(Withaferin A)
3 Isoliquiritigenin
3 Magnolol
3 Shikonin
3 Thymoquinone
3 Vitamin C (Ascorbic Acid)
3 Vitexin
2 Allicin (mainly Garlic)
2 Berberine
2 Betulinic acid
2 Metformin
2 Centella asiatica / Gotu kola → asiaticoside
2 Chlorogenic acid
2 Ellagic acid
2 Eugenol
2 Radiotherapy/Radiation
2 Ferulic acid
2 Graviola
2 doxorubicin
2 Lycopene
2 Methylene blue
2 Melatonin
2 chitosan
2 Selenium NanoParticles
2 Taurine
1 5-Aminolevulinic acid
1 Anthocyanins
1 entinostat
1 Glucose
1 Ajoene (compound of Garlic)
1 Alpha-Lipoic-Acid
1 Anethole/trans-Anethole
1 Artemisinin
1 2-DeoxyGlucose
1 Baicalein
1 Boswellia (frankincense)
1 brusatol
1 Brucea javanica
1 Caffeic acid
1 NTP, Non-Thermal Plasma,Cold Atmospheric Plasma
1 Thymol-Thymus vulgaris
1 Chrysin
1 Citric Acid
1 Crocetin
1 Curcumin
1 Dichloroacetate
1 Docosahexaenoic Acid
1 D-limonene
1 EGCG (Epigallocatechin Gallate)
1 Cisplatin
1 Fisetin
1 Gallic acid
1 Honokiol
1 Hyperoside
1 isoorientin
1 Ivermectin
1 lambertianic acid
1 Licochalcone A
1 SDG/lignans
1 Photodynamic Therapy
1 Magnetic Fields
1 Methylglyoxal
1 Marjoram (Origanum majorana)
1 Phenylbutyrate
1 Piperlongumine
1 Psoralidin
1 Resveratrol
1 salinomycin
1 Selenium
1 polyethylene glycol
1 Sulforaphane (mainly Broccoli)
1 Silymarin (Milk Thistle) silibinin
1 5-fluorouracil
1 Wogonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:906  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page